

- **Name:** Steven Maron
- **Current Position & Affiliation:** Assistant Member, Memorial Sloan Kettering Cancer Center (MSK)
Assistant Professor of Medicine, Weill Cornell Medical College
- **Country:** USA

• **Educational Background:**

Degree (include field of study)	Institution Name & Location	Dates Attended	Year Awarded
BS, Food Science	Cornell University - Ithaca, NY	2003 - 2006	2006
MD	Jefferson Medical College - Philadelphia, PA	2007 - 2011	2011
MSc, Biomedical Informatics	University of Chicago, Chicago - Chicago, IL	2016 - 2018	2018

• **Professional Experience:**

Academic Appointments

Title	Institution, City and State	Dates Attended
Clinical Instructor/Coggeshall Research Fellow	University Of Chicago - Chicago, IL	2017 - 2018
Assistant Member	Memorial Sloan Kettering Cancer Center - New York, NY	2023 - Present
Assistant Professor of Medicine	Weill Cornell Medical College - New York, NY	2023 - Present

Hospital Appointments

Title	Institution, City and State	Dates Attended
Instructor	University of Chicago Medical Center - Chicago, IL	2017 - 2018
Assistant Attending Physician	Memorial Hospital for Cancer and Allied Diseases - New York, NY	2019 - Present

• **Professional Organizations:**

Organization	Date
Alpha Omicron Omega (AOA)	2010 - Present
American Society of Clinical Oncology (ASCO)	2014 - Present
American Association of Cancer Research (AACR)	2016 - Present

• Main Scientific Publications:

1. **Maron SB**, Chatila W, Walch H, Chou JF, Ceglia N, Ptashkin R, Do RKG, Paroder V, Pandit-Taskar N, Lewis JS, Biachi De Castria T, Sabwa S, Socolow F, Feder L, Thomas J, Schulze I, Kim K, Elzein A, Bojilova V, Zatzman M, Bhanot U, Nagy RJ, Lee J, Simmons M, Segal M, Ku GY, Ilson DH, Capanu M, Hechtman JF, Merghoub T, Shah S, Schultz N, Solit DB, Janjigian YY. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer. *Clin Cancer Res.* 2023 Sep 15;29(18):3633–3640. PMID: PMC10502449
2. Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, **Maron SB**, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. *Lancet Oncol.* 2023 Oct;24(10):1073–1082. PMID: 37666264
3. Magahis PT, **Maron SB**, Cowzer D, King S, Schattner M, Janjigian Y, Faleck D, Laszkowska M. Impact of *Helicobacter pylori* infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. *J Immunother Cancer.* 2023 Oct;11(10). PMID: PMC10619027
4. Lumish MA, Walch H, **Maron SB**, Chatila W, Kemel Y, Maio A, Ku GY, Ilson DH, Won E, Li J, Joshi SS, Gu P, Schattner MA, Laszkowska M, Gerdes H, Jones DR, Sihag S, Coit DG, Tang LH, Strong VE, Molena D, Stadler ZK, Schultz N, Janjigian YY, Cercek A. Clinical and Molecular Characteristics of Early-Onset versus Average-Onset Esophagogastric Cancer. *J Natl Cancer Inst.* 2023 Sep 12; PMID: 37699004
5. Cytryn SL, Pandit-Taskar N, Lumish MA, **Maron SB**, Gu P, Ku GY, Chou JF, Capanu M, Antoine A, Loegel D, Feder L, Philemond S, Lyashchenko SK, Lewis JS, Paroder V, Srivastava A, Tang LH, Schoder H, Janjigian YY. 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. *J Nucl Med.* 2024 May 1;65(5):722–727. PMID: PMC11064823
6. Vitiello GA, Jayaprakasam VS, Tang LH, Schattner MA, Janjigian YY, Ku GY, **Maron SB**, Schoder H, Larson SM, Gönen M, Datta J, Coit DG, Brennan MF, Strong VE. Patient metabolic profile defined by liver and muscle 18F-FDG PET avidity is independently associated with overall survival in gastric cancer. *Gastric Cancer.* 2024 May;27(3):548–557. PMID: 38436762
7. Shariff B, Barnett RM, Dayyani F, **Maron SB**, Mcgriskin R, Klempner S, Donderici EY, Zhang N, Masannat J, Drusbosky LM, Mehta R. Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers. *Oncologist.* 2024 Aug 5;29(8):672–680. PMID: PMC11299948

8. Gui C, Walch HS, Mueller KD, Boe LA, Ilica AT, Strong J, Eichholz JE, Yu KKH, Wilcox JA, Manca P, Yu Y, Yamada Y, Imber BS, **Maron SB**, Foote MB, Yaeger R, Schultz N, Pike LRG. Clinicogenomic predictors of survival and intracranial progression after stereotactic radiosurgery for colorectal cancer brain metastases. *J Neurosurg.* 2024 Aug 30;1–11. PMID: 39213675

9. Sewell M, Toumbacaris N, Tan KS, Bahadur N, Philip J, Shah NJ, Niederhausern A, Martinez CT, Zheng H, Boerner T, Janjigian YY, **Maron SB**, Bott MJ, Gray KD, Park BJ, Sihag S, Jones DR, Ku GY, Wu AJ, Molena D. Esophagectomy may have a role in stage IV esophageal adenocarcinoma. *J Thorac Cardiovasc Surg.* 2024 Nov 22; PMID: 39581309

10. Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, Fu C, Altoe M, Liu S-Y, **Maron SB**, Ahmed M, Kim S, Pirun M, Chatila WK, de Bruijn I, Pasha A, Kundra R, Gross B, Mastrogiacomo B, Aprati TJ, Liu D, Gao J, Capelletti M, Pekala K, Loudon L, Perry M, Bandlamudi C, Donoghue M, Satravada BA, Martin A, Shen R, Chen Y, Brannon AR, Chang J, Braunstein L, Li A, Safonov A, Stonestrom A, Sanchez-Vela P, Wilhelm C, Robson M, Scher H, Ladanyi M, Reis-Filho JS, Solit DB, Jones DR, Gomez D, Yu H, Chakravarty D, Yaeger R, Abida W, Park W, O'Reilly EM, Garcia-Aguilar J, Socci N, Sanchez-Vega F, Carrot-Zhang J, Stetson PD, Levine R, Rudin CM, Berger MF, Shah SP, Schrag D, Razavi P, Kehl KL, Li BT, Riely GJ, Schultz N, MSK Cancer Data Science Initiative Group. Automated real-world data integration improves cancer outcome prediction. *Nature.* 2024 Nov 6; PMID: 39506116

11. Magahis PT, Cornet N, Tang L, Arora K, Hingorani N, King S, Markowitz AJ, Schattner M, Shimada S, **Maron SB**, Vardhana S, Lumish M, Cercek A, Janjigian YY, Coit D, Mendelsohn RB, Berger MF, Strong VE, Stadler ZK, Laszkowska M. Differences in Ancestry and Presence of Gastric Precursor Lesions in Individuals With Young- and Average-Onset Gastric Cancer. *Cancer Med.* 2024 Dec;13(23):e70451. PMCID: PMC11615756